Atossa Therapeutics (NASDAQ:ATOS) Price Target Raised to $7.00 at Ascendiant Capital Markets

Atossa Therapeutics (NASDAQ:ATOS) had its price target increased by Ascendiant Capital Markets from $6.50 to $7.00 in a research report sent to investors on Monday,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

ATOS has been the topic of several other reports. HC Wainwright upped their target price on Atossa Therapeutics from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. StockNews.com downgraded shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, November 18th.

Atossa Therapeutics Trading Up 2.5 %

Shares of ATOS stock opened at $1.25 on Monday. Atossa Therapeutics has a 12-month low of $0.70 and a 12-month high of $2.31. The business’s fifty day simple moving average is $1.38 and its 200-day simple moving average is $1.33. The company has a market cap of $157.25 million, a PE ratio of -5.68 and a beta of 1.22.

Hedge Funds Weigh In On Atossa Therapeutics

Several hedge funds have recently made changes to their positions in ATOS. Barclays PLC grew its stake in Atossa Therapeutics by 280.9% during the 3rd quarter. Barclays PLC now owns 167,718 shares of the company’s stock valued at $255,000 after purchasing an additional 123,683 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Atossa Therapeutics by 1.6% during the third quarter. Geode Capital Management LLC now owns 2,814,446 shares of the company’s stock worth $4,278,000 after purchasing an additional 44,762 shares during the period. XTX Topco Ltd boosted its position in Atossa Therapeutics by 101.2% in the third quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock valued at $75,000 after buying an additional 24,951 shares during the last quarter. State Street Corp increased its holdings in Atossa Therapeutics by 4.2% in the 3rd quarter. State Street Corp now owns 1,732,221 shares of the company’s stock worth $2,633,000 after buying an additional 69,180 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new position in Atossa Therapeutics during the 3rd quarter worth approximately $75,000. 12.74% of the stock is owned by institutional investors and hedge funds.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.